What is the 5‑year overall and disease‑free survival prognosis for a 64‑year‑old otherwise healthy patient with resected stage III melanoma (substage IIIA‑IIID) receiving adjuvant pembrolizumab?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prognosis for Stage III Melanoma with Adjuvant Pembrolizumab

For a 64-year-old otherwise healthy patient with resected stage III melanoma receiving adjuvant pembrolizumab, the 5-year overall survival ranges from approximately 50-70% depending on substage, with 5-year recurrence-free survival of 55.4% and distant metastasis-free survival of 60.6%. 1, 2

Survival Outcomes by Substage

Stage III melanoma encompasses a highly heterogeneous population with dramatically different prognoses based on substage 3:

  • Stage IIIA: 5-year survival rates of 70-80% 3
  • Stage IIIB: 5-year survival rates of 50-70% 3
  • Stage IIIC: 5-year survival rates of 40-50% 3
  • Stage IIID: 5-year survival rates of 30-40% with surgery alone, improving to 50-70% with adjuvant pembrolizumab 2

Pembrolizumab-Specific Survival Data

The landmark EORTC 1325/KEYNOTE-054 trial provides the most robust long-term data for adjuvant pembrolizumab in stage III melanoma 1, 4, 5:

5-Year Outcomes (Primary Analysis)

  • 5-year recurrence-free survival: 55.4% with pembrolizumab vs. 38.3% with placebo (HR 0.61,95% CI 0.51-0.72) 1
  • 5-year distant metastasis-free survival: 60.6% with pembrolizumab vs. 44.5% with placebo (HR 0.62,95% CI 0.52-0.75) 1

7-Year Outcomes (Extended Follow-up)

  • 7-year recurrence-free survival: 50% with pembrolizumab vs. 36% with placebo (HR 0.63,95% CI 0.53-0.74) 5
  • 7-year distant metastasis-free survival: 54% with pembrolizumab vs. 42% with placebo (HR 0.64,95% CI 0.54-0.76) 5

3.5-Year Outcomes (Intermediate Analysis)

  • 3.5-year distant metastasis-free survival: 65.3% with pembrolizumab vs. 49.4% with placebo (HR 0.60,95% CI 0.49-0.73) 4

Disease-Free Survival by Substage with Pembrolizumab

The EORTC 1325 trial demonstrated consistent benefit across all stage III substages 3:

  • Stage IIIA: HR 0.58 for recurrence-free survival 3
  • Stage IIIB: HR 0.58 for recurrence-free survival 3
  • Stage IIIC: HR 0.38 for recurrence-free survival 3

Age-Specific Considerations for 64-Year-Old Patients

Performance status and comorbidities are more predictive of outcomes than chronologic age alone. 2

  • Patients with ECOG performance status 0-1 tolerate and benefit from adjuvant immunotherapy regardless of age 2
  • Grade 3-4 adverse events occur in 11-54% of patients on pembrolizumab, with permanent discontinuation rates of 11-14% 2
  • At age 64, this patient falls within the median age range (61 years) of the KEYNOTE-054 trial, suggesting excellent applicability of trial results 6

Comparison to Historical Outcomes

Without modern adjuvant therapy, stage III melanoma historically showed 3:

  • 5-year survival rates: 20-70% depending on nodal tumor burden 3
  • Stage IIIA: Approximately 70% 5-year survival 3
  • Stage IIIB: Approximately 50% 5-year survival 3
  • Stage IIIC: Approximately 30-40% 5-year survival 3

Adjuvant pembrolizumab represents a 17.1% absolute improvement in 5-year recurrence-free survival and a 16.1% absolute improvement in 5-year distant metastasis-free survival compared to placebo. 1

Critical Prognostic Factors Beyond Stage

Several factors modify prognosis within stage III disease 3:

  • Number of positive lymph nodes: 1-3 nodes vs. ≥4 nodes significantly impacts survival 3
  • Microscopic vs. macroscopic nodal involvement: Sentinel node micrometastases have better prognosis than clinically detected macrometastases 3
  • Ulceration of primary tumor: Presence of ulceration worsens prognosis 3
  • Primary tumor thickness: T4 tumors (>4mm) have worse outcomes 2
  • PD-L1 status: Both PD-L1 positive and negative patients benefit from pembrolizumab, though PD-L1 positive showed 61.4% vs. 44.1% 3.5-year RFS 4

Treatment Duration and Compliance

Pembrolizumab is administered at 200 mg intravenously every 3 weeks for 18 doses (approximately 1 year). 3, 1

  • Treatment completion rates are significantly higher than with older interferon regimens 3
  • The benefit persists years after treatment completion, as demonstrated by sustained 7-year outcomes 5

Common Pitfalls to Avoid

Do not underestimate the importance of completing the full 1-year course of adjuvant pembrolizumab. 2

  • Early discontinuation due to manageable toxicities may compromise long-term outcomes 2
  • Proactive management of immune-related adverse events is essential 7
  • Monitor for colitis, hepatitis, pneumonitis, endocrinopathies, and dermatologic toxicities 7

Do not delay treatment initiation after surgical recovery. 7

  • Starting adjuvant treatment promptly optimizes outcomes 7
  • All major trials mandated complete lymphadenectomy before enrollment, though this practice is evolving 3

References

2
Guideline

Life Expectancy and Treatment Guidelines for Stage IIID Melanoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

7
Guideline

Adjuvant Therapy for Triple Wild-Type Melanoma with Resected Lung Metastases

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the best course of treatment for a 62-year-old female patient with malignant melanoma of the left lower limb, experiencing pain and swelling due to fluid reaccumulation after undergoing wide local excision, sentinel lymph node biopsy, and sclerotherapy, and currently on pembrolizumab (pembrolizumab) and having completed a course of antibiotics?
What were the eligibility criteria, dosing regimen, and primary outcomes of the SWOG S1801 trial evaluating neoadjuvant pembrolizumab (Keytruda) for resectable stage III (IIIB–IIIC) or oligometastatic stage IV cutaneous melanoma?
Can amoxicillin-clavulanate be administered concurrently with linezolid?
In a patient with acute hydrogen fluoride inhalation injury who develops severe hypoxemic respiratory failure refractory to optimal lung‑protective ventilation, should early veno‑venous extracorporeal membrane oxygenation (VV‑ECMO) be initiated as rescue therapy?
Is clindamycin effective against methicillin‑resistant Staphylococcus aureus (MRSA) and can it replace linezolid?
What are the current evidence‑based guidelines for managing dyslipidemia, including lifestyle modification, risk assessment, statin therapy, and use of non‑statin agents?
What are the differences in pathophysiology, clinical course, and immediate management between hydrogen fluoride inhalation injury and phosgene inhalation injury?
What is the proper preparation and administration of 5% dextrose in half‑strength normal saline for a patient with diabetic ketoacidosis whose plasma glucose is about 200‑250 mg/dL while receiving a regular insulin infusion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question